Lineage Cell Therapeutics, Inc. (LCTX) Form 10-Q — May 12, 2026
Lineage Cell Therapeutics, Inc. reported a net loss of $4.812 million for the three months ended March 31, 2026, compared to a net loss of $4.139 million for the same period in 2025. The company's total revenue increased by 15% to $1.725 million in the first quarter of 2026, driven by a $0.3 million increase in collaboration revenues from the WDI collaboration. The company's cash position as of March 31, 2026, was $35.939 million, down from $40.791 million at the end of 2025.
Key figures
- Eps Beat
- 0
- Revenue
- 1725
- Total Debt
- 56838
- Debt Amount
- 0
- Revenue Yoy
- 15
- Total Assets
- 109533
- Cash Position
- 35939
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 249298295
- Warrant Liabilities
- 34140
- Marketable Securities
- 17442
Price after filing
Close on the filing date to close N calendar days later (from $1.33). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.